<DOC>
	<DOCNO>NCT01998165</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety JNJ-268229 ( Ultiva /Remifentanil Hydrochloride ) pediatric participant 1 15 year age maintenance general anesthesia .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Ultiva ( Remifentanil Hydrochloride ) Pediatric Participants General Anesthetised</brief_title>
	<detailed_description>This multicenter , open-label ( identity assign study drug know ) one-arm study pediatric participant receive general anesthesia . The participant child age 1-15 year old , plan undergo head neck , thoracic ( except heart ) , urological , orthopedic plastic surgery . Approximately 80 participant enrol study . These participant divide two group age ( 1-6 7-15 year old ) . Pharmacokinetic ( body drug , ) blood sample collect least 3 participant age 1 6 year least 3 participant age 7 15 year 15 minute start infusion end infusion study drug . The study consist 4 phase : screening phase , treatment phase , recovery phase follow-up phase . Screening eligible participant perform within 14 day administration study drug . The safety tolerability study drug evaluate physical examination , electrocardiogram ( ECG ) , clinical laboratory test , vital sign , adverse event ( AEs ) accord Time Events Schedule . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Participants schedule receive surgery general anesthesia , necessitate airway secure tracheal intubation analgesia opioid analgesic American Society Anesthesiologists ( ASA ) Physical Status Classification I II time operation plan Participants schedule receive operation estimate take 30 minute skin incision i.e . Head neck , thoracic ( except heart ) , intraperitoneal , ophthalmological , otorhinolaryngological , urological , orthopedic plastic surgery Girls undergone menarche eligible urine pregnancy test time screen negative Chronic use opioid analgesic use within 12 hour plan start general anesthesia Hypersensitivity opioid analgesic local anesthetic History jaundice unexplained fever induce halogenated anesthetic Unstable hemodynamics ( eg . congenital heart disease , congenital diaphragmatic hernia ) Ideal body weight within 10th 90th percentile receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 90 day plan first dose study drug currently enrol investigational study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Anesthesia</keyword>
	<keyword>Remifentanil</keyword>
	<keyword>Ultiva</keyword>
</DOC>